Xyzal Articles
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
Belgium’s UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
1 February 2010
US FDA clears UCB/Sanofi-Aventis’ Xyzal for children
25 August 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
Perrigo gets rights to allergy drug from Synthon
15 September 2008
UCB's 2007 net profit down 59% on M&A
10 March 2008
Xyzal oral solution cleared by US FDA
25 February 2008
UCB's 1st-half profits fall 39% on Schwarz buy
6 August 2007
FDA OKs UCB/Sanofi's Xyzal for allergies
4 June 2007
Cimzia key drug in UCB 2007 R&D update
7 May 2007
S-P's Aeris less side effects than Xyzal
11 December 2006
Sanofi and UCB enter US co-promotion deal for Xyzal
2 October 2006
Belgium's UCB submits Xyzal NDA to FDA
7 August 2006
UCB 1st-half results ahead of forecasts
7 August 2006
UCB and Sepracor extend levocetirizine accord
27 February 2006
UCB projects income of 260 M euros for 2005
19 December 2005
UCB's PAR drug Xyza performs well in trials
5 December 2005
UCB confirms strong US sales of Zyrtec
25 July 2005
UCB confirms Zyrtec sales performance
24 January 2005
UCB's Xyzal wins in head-to-head with S-P's Aerius
15 March 2004
Zyrtec continues to drive UCB pharma
17 February 2003
Profits on the increase at Belgium's UCB Group
15 April 2002
Zyrtec driving sales and earnings at UCB
18 February 2002
UCB to post 20% profit growth in 2001
12 December 2001
Xyzal launched in UK
2 October 2001
UCB's Xyzal cleared for marketing in EU
31 August 2001
Update: UCB 1st-half pharma turnover leaps 31%
31 July 2001
UCB 1st-half pharma sales leap 31%
30 July 2001
UCB 1st-half pharma sales leap 31%
27 July 2001
Good start to 2001 for UCB pharma
15 June 2001
UCB profits up 23% in 2000
11 April 2001
Sepracor files NDA for norastemizole
13 March 2001
UCB reports 27% growth in pretax profit
31 July 2000
Showing 1-41 of 41 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
